Sage Therapeutics Inc.

11/20/2024 | Press release | Distributed by Public on 11/20/2024 06:02

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.